Skip to contents

Nina P. Paynter, PhD
Associate Epidemiologist, Brigham and Women's Hospital
Lecturer on Medicine, Part-time, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Preventive Medicine
75 Francis Street
Boston, MA 02115

Edit Profile

Research Narrative:

Dr. Paynter's main research interests are the interrelationship of the major cardiovascular risk factors (including type 2 diabetes, blood pressure, lipids, inflammation, body mass index, exercise, and diet) and the effects of genetic and metabolomic factors on these interrelationships.  Her work has been focused primarily on cardiovascular risk prediction and has also included development and evaluation of risk prediction methods. She also serves as the Associate Director of the Data Coordinating Center for the Cardiovascular Inflammation Reduction Trial.

Johns Hopkins University, 2007, PhD, Epidemiology
Johns Hopkins School of Public Health, 2005, MHS, Biostatistics

Publications (Pulled from Harvard Catalyst Profiles):

1. Solomon DH, Shao M, Wolski K, Nissen S, Husni ME, Paynter N. Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. Arthritis Rheumatol. 2019 Aug; 71(8):1225-1231.

2. Xu H, Qian J, Paynter NP, Zhang X, Whitcomb BW, Tworoger SS, Rexrode KM, Hankinson SE, Balasubramanian R. Estimating the receiver operating characteristic curve in matched case control studies. Stat Med. 2019 Feb 10; 38(3):437-451.

3. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 02 21; 380(8):752-762.

4. Leening MJG, Cook NR, Franco OH, Manson JE, Lakshminarayan K, LaMonte MJ, Leira EC, Robinson JG, Ridker PM, Paynter NP. Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women. J Am Heart Assoc. 2018 Oct 02; 7(19):e007514.

5. Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Ridker PM. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018 12; 206:80-93.

6. Mora S, Wenger NK, Cook NR, Liu J, Howard BV, Limacher MC, Liu S, Margolis KL, Martin LW, Paynter NP, Ridker PM, Robinson JG, Rossouw JE, Safford MM, Manson JE. Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative. JAMA Intern Med. 2018 Sep 01; 178(9):1231-1240.

7. Demler OV, Paynter NP, Cook NR. Reclassification calibration test for censored survival data: performance and comparison to goodness-of-fit criteria. Diagn Progn Res. 2018; 2.

8. Paynter NP, Balasubramanian R, Giulianini F, Wang DD, Tinker LF, Gopal S, Deik AA, Bullock K, Pierce KA, Scott J, Martínez-González MA, Estruch R, Manson JE, Cook NR, Albert CM, Clish CB, Rexrode KM. Metabolic Predictors of Incident Coronary Heart Disease in Women. Circulation. 2018 02 20; 137(8):841-853.

9. Cook NR, Demler OV, Paynter NP. Clinical risk reclassification at 10 years. Stat Med. 2017 Dec 10; 36(28):4498-4502.

10. Paynter NP. Cardiovascular Risk Prediction: Widening the Net. Circ Res. 2017 10 13; 121(9):1032-1033.